Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations

Atherosclerosis. 1999 Sep;146(1):153-60. doi: 10.1016/s0021-9150(99)00113-6.

Abstract

The promoter sequence variant -480T in the hepatic lipase gene (LIPC) has been shown to be significantly associated with low post-heparin hepatic lipase activity. Some studies have also found that the -480T variant is associated with elevation in plasma HDL cholesterol. We tested for associations of LIPC -480T with plasma lipoprotein traits in samples taken from three distinct Canadian populations: 657 Alberta Hutterites, 328 Ontario Oji-Cree and 210 Keewatin Inuit. Plasma HL activity was not available for analyses. The LIPC -480T allele frequencies in these three groups, respectively, were 0.219, 0.527 and 0.383, and the prevalence of LIPC -480T/T homozygotes was, respectively, 0.042, 0.274 and 0.167. No significant association was found between LIPC -480T and plasma HDL cholesterol or apolipoprotein AI concentration, after adjusting for covariates including gender and body mass index. There was no consistent relationship between the population mean plasma HDL cholesterol concentration and the population LIPC -480T frequency. Our findings are consistent with the idea that the common promoter variation in LIPC, which has been reported to be associated with variation in post heparin HL activity and HDL triglyceride concentration, is not always associated with variation in plasma HDL cholesterol concentration, possibly due to yet unspecified environmental or genetic factors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Arteriosclerosis / genetics
  • Canada
  • Cholesterol, HDL / blood*
  • Female
  • Gene Frequency
  • Genetic Variation*
  • Humans
  • Indians, North American / genetics*
  • Lipase / blood
  • Lipase / genetics*
  • Liver / enzymology*
  • Male
  • Middle Aged
  • Phenotype
  • Population Surveillance
  • Promoter Regions, Genetic*
  • Sensitivity and Specificity
  • Transcriptional Activation

Substances

  • Cholesterol, HDL
  • Lipase